US Edition
Published • loading... • Updated
Briumvi outperforms Aubagio in highly active relapsing MS: Study
Summary by Multiple Sclerosis News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Briumvi outperforms Aubagio in highly active relapsing MS: Study
The CD20 inhibitor Briumvi (ublituximab) significantly outperformed Aubagio (teriflunomide) at lowering relapse rates and reducing disease activity on brain MRI scans in people with highly active relapsing forms of multiple sclerosis (MS). That’s according to a new analysis of pooled data from the ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248) Phase 3 clinical studies, which […] The post Briumvi outperforms Aubagio in highly active relap…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
